This information was published, 2016-09-26 08:30 CEST (GLOBE NEWSWIRE) --
The presented data continues to support the place of the Episealer implant as a necessary treatment option for patients with focal cartilage damage of the knee joint. The results underline that the implant is proving to be a safe intervention for hard-to-treat middle-aged patients with cartilage damage and that significant improvements in knee function and quality of life can be expected.
“The results of this scientific abstract, being presented to leading cartilage repair surgeons from around the world, continue to support the safety and efficacy of the Episealer device for cartilage damage. In patients with the right indication, we believe Episealer has the potential to slow down and possibly halt the destructive process that leads to osteoarthritis” says Professor Leif Ryd, Senior Medical Advisor for Episurf Medical. “The science behind the Episealer, coupled with the ongoing clinical data collection that we undertake, is now demonstrating that Episealer can offer significant benefits to patients with chondral defects. These are exciting times”.
The presentation supports the findings and comments delivered earlier during the ICRS congress when a highly respected faculty of cartilage-repair surgeons delivered Episurf Medicals’s first ever educational symposium. “ICRS is proving to be a landmark event for us. Gaining the trust of cartilage surgeons is key to the success of Episurf Medical.” comments Rosemary Cunningham Thomas, CEO of Episurf Medical. “Continued clinical data, like this, that reports good outcomes for our patients, coupled with delivering exceptional education for our customers means Episurf is starting to truly be recognized as a valued partner for cartilage-repair surgeons”, concludes Rosemary Cunningham Thomas.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
Email: rosemary@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.
